Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Withdrawn before enrolling · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining the monoclonal antibody rituximab with dexamethasone may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and dexamethasone in treating patients with recurrent or refractory indolent non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00003663

Run by

Hoag Memorial Hospital Presbyterian

People needed

0

Starts

1998-06-01

Expected to finish

2000-01-01

Last updated by the study team

2015-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• Cancer Care Center for Southern Indiana — Bloomington, Indiana, United States
• St. Joseph Regional Cancer Center — Bryan, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.